1. Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth

4. Program Goals

5. The Growing Diabetes Pandemic

6. Approved Antidiabetic Medications

7. Cardiovascular benefits to tighter HbA1c control?

8. Outcomes of Better Glycemic Control in T2D: UKPDS and Post-UKPDS

9. Should Hyperglycemia in Diabetes Be Treated Aggressively?

10. DCCT/EDIC: Intensive Diabetes Therapy in T1D

12. Counseling a Patient With Newly Diagnosed T2D

13. Sulfonylureas

14. Safety of Sulfonylureas

15. Safety of Sulfonylureas (cont)

16. The CAROLINA Study: Phase 3 Results

17. Rosiglitazone Data Reanalyzed

18. Results of a Reevaluation of Cardiovascular Outcomes in the RECORD Trial

19. Thiazolidinediones

20. Pioglitazone: The PROactive Study

21. Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat T2D

22. Impact of FDA Guidance: December 2008

23. Incretin-Based Drugs

24. Incretin-Based Drugs (cont)

25. Warnings and Precautions

26. SGLT-2 Inhibitors

27. SGLT-2 Inhibitors (cont)

28. SAVOR-TIMI 53 trial

29. Take-Home Messages

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)

33. References

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)